Stratec Biomedical AG (SBS) Given Consensus Rating of “Hold” by Analysts
Stratec Biomedical AG (ETR:SBS) has been assigned an average recommendation of “Hold” from the six analysts that are covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is €59.33 ($69.80).
A number of equities research analysts have recently issued reports on the company. Oddo Bhf set a €58.00 ($68.24) target price on Stratec Biomedical AG and gave the company a “neutral” rating in a research note on Monday. Deutsche Bank AG set a €55.00 ($64.71) target price on Stratec Biomedical AG and gave the company a “neutral” rating in a research note on Thursday, July 27th. Berenberg Bank set a €57.00 ($67.06) target price on Stratec Biomedical AG and gave the company a “neutral” rating in a research note on Monday. Kepler Capital Markets set a €66.00 ($77.65) target price on Stratec Biomedical AG and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, Oddo Securities set a €58.00 ($68.24) target price on Stratec Biomedical AG and gave the company a “neutral” rating in a research note on Monday, July 24th.
Stratec Biomedical AG (ETR:SBS) opened at 57.122 on Monday. The firm has a market capitalization of €679.07 million and a P/E ratio of 35.282. The stock’s 50 day moving average price is €53.11 and its 200-day moving average price is €55.23. Stratec Biomedical AG has a 12 month low of €41.45 and a 12 month high of €63.18.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/stratec-biomedical-ag-sbs-given-consensus-rating-of-hold-by-analysts.html.
Stratec Biomedical AG Company Profile
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.
Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.